Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia-Reference-Cited by-同舟云学术

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia

Published:2018-11-16 Issue:11 Volume:2018 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Pattanaik Smita¹,Mavuduru Ravimohan S²,Panda Arabind³,Mathew Joseph L⁴,Agarwal Mayank M²,Hwang Eu Chang⁵,Lyon Jennifer A⁶,Singh Shrawan K²,Mandal Arup K²

Affiliation:

1. Post Graduate Institute of Medical Education and Research; Department of Pharmacology; Chandigarh India 160012

2. Post Graduate Institute of Medical Education and Research; Department of Urology; Chandigarh India

3. Christian Medical College; Department of Urology; Vellore India

4. Post Graduate Institute of Medical Education and Research; Department of Pediatrics; Chandigarh India 160012

5. Chonnam National University Medical School, Chonnam National University Hwasun Hospital; Department of Urology; Hwasun Korea, South

6. Children's Mercy Hospital; Library Services; 2401 Gillham Road Kansas City Missouri USA 64118

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010060.pub2/epdf/full

Reference177 articles.

1. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study;Bechara;Journal of Sexual Medicine,2008

2. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction;Brock;BJU International,2013

3. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia;Casabe;Journal of Urology,2014

4. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial;Dmochowski;Journal of Urology,2010

5. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study;Egerdie;Journal of Sexual Medicine,2012

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Konservative und medikamentöse Therapie des benignen Prostatasyndroms;Die Urologie;2023-10

2. Overview of current pharmacotherapeutic options in benign prostatic hyperplasia;Expert Opinion on Pharmacotherapy;2023-07-21

3. MRI of Benign Prostatic Hyperplasia: Important Pre- and Posttherapeutic Considerations;RadioGraphics;2023-05-01

4. Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003;Frontiers in Pharmacology;2023-04-28

5. What is new in the pharmacotherapy of benign prostatic hyperplasia;Klinická farmakologie a farmacie;2023-04-21